These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18334586)

  • 1. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
    Quinkler M; Hahner S; Wortmann S; Johanssen S; Adam P; Ritter C; Strasburger C; Allolio B; Fassnacht M
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2057-62. PubMed ID: 18334586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
    Sperone P; Ferrero A; Daffara F; Priola A; Zaggia B; Volante M; Santini D; Vincenzi B; Badalamenti G; Intrivici C; Del Buono S; De Francia S; Kalomirakis E; Ratti R; Angeli A; Dogliotti L; Papotti M; Terzolo M; Berruti A
    Endocr Relat Cancer; 2010 Jun; 17(2):445-53. PubMed ID: 20410174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.
    Wortmann S; Quinkler M; Ritter C; Kroiss M; Johanssen S; Hahner S; Allolio B; Fassnacht M
    Eur J Endocrinol; 2010 Feb; 162(2):349-56. PubMed ID: 19903796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors.
    Henning JEK; Deutschbein T; Altieri B; Steinhauer S; Kircher S; Sbiera S; Wild V; Schlötelburg W; Kroiss M; Perotti P; Rosenwald A; Berruti A; Fassnacht M; Ronchi CL
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4323-4332. PubMed ID: 29092062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
    Gatzemeier U; Pluzanska A; Szczesna A; Kaukel E; Roubec J; De Rosa F; Milanowski J; Karnicka-Mlodkowski H; Pesek M; Serwatowski P; Ramlau R; Janaskova T; Vansteenkiste J; Strausz J; Manikhas GM; Von Pawel J
    J Clin Oncol; 2007 Apr; 25(12):1545-52. PubMed ID: 17442998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
    You B; Le Tourneau C; Chen EX; Wang L; Jarvi A; Bharadwaj RR; Kamel-Reid S; Perez-Ordonez B; Mann V; Siu LL
    Am J Clin Oncol; 2012 Jun; 35(3):255-60. PubMed ID: 21358293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
    Wu YL; Lee JS; Thongprasert S; Yu CJ; Zhang L; Ladrera G; Srimuninnimit V; Sriuranpong V; Sandoval-Tan J; Zhu Y; Liao M; Zhou C; Pan H; Lee V; Chen YM; Sun Y; Margono B; Fuerte F; Chang GC; Seetalarom K; Wang J; Cheng A; Syahruddin E; Qian X; Ho J; Kurnianda J; Liu HE; Jin K; Truman M; Bara I; Mok T
    Lancet Oncol; 2013 Jul; 14(8):777-86. PubMed ID: 23782814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy.
    Grisanti S; Cosentini D; Laganà M; Morandi A; Lazzari B; Ferrari L; Volta AD; Ambrosini R; Ferrari VD; Sigala S; Berruti A
    Front Endocrinol (Lausanne); 2021; 12():624102. PubMed ID: 33716976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
    Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
    J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.
    Kroiss M; Megerle F; Kurlbaum M; Zimmermann S; Wendler J; Jimenez C; Lapa C; Quinkler M; Scherf-Clavel O; Habra MA; Fassnacht M
    J Clin Endocrinol Metab; 2020 May; 105(5):1461-8. PubMed ID: 31900481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2
    Zhong WZ; Chen KN; Chen C; Gu CD; Wang J; Yang XN; Mao WM; Wang Q; Qiao GB; Cheng Y; Xu L; Wang CL; Chen MW; Kang X; Yan W; Yan HH; Liao RQ; Yang JJ; Zhang XC; Zhou Q; Wu YL
    J Clin Oncol; 2019 Sep; 37(25):2235-2245. PubMed ID: 31194613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W;
    J Clin Oncol; 2007 May; 25(15):1960-6. PubMed ID: 17452677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
    Boeck S; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler T; Fischer von Weikersthal L; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Neugebauer S; Heinemann V
    Anticancer Drugs; 2010 Jan; 21(1):94-100. PubMed ID: 19770635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
    Monti DA; Mitchell E; Bazzan AJ; Littman S; Zabrecky G; Yeo CJ; Pillai MV; Newberg AB; Deshmukh S; Levine M
    PLoS One; 2012; 7(1):e29794. PubMed ID: 22272248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.